Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection.
J Immunother Cancer. 2021 Jan;9(1):e001225. doi: 10.1136/jitc-2020-001225.
J Immunother Cancer. 2021.
PMID: 33472856
Free PMC article.